Drug intelligence / Profile preview

Relief Active Product 3

Development stage: Preclinical
Lead developer: Radicle Science
Administration: Oral

Overview

Relief Active Product 3 is a dietary supplement developed by Radicle Science. It is currently being investigated in a randomized, double-blind, placebo-controlled direct-to-consumer study (Radicle Relief 24_RLN) to assess its impact on pain and related health outcomes. Participants in the study are directed to use the product for a period of 6 weeks.

Beyond the preview

Go deeper on Relief Active Product 3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Relief Active Product 3.

Explore the full profile